Dentsply Sirona (XRAY) reported third-quarter adjusted earnings of $0.29 per share on revenue of $836.0 million. Both figures missed consensus: EPS fell short by 3.3% against the $0.30 estimate, and revenue came in 2.3% below the $855.98 million forecast. Earnings fell 21.6% year over year and revenue declined 7.5%. The company's own non-GAAP comparison is harsher. It shows adjusted EPS falling to $0.29 from a restated $0.42, a 29.4% decline. The bigger news was guidance. After reaffirming its fiscal 2026 outlook for three straight quarters, management cut adjusted EPS guidance to $1.20-$1.30 from $1.40-$1.50 and pushed revenue to the low end of its range, at roughly $3.5 billion. The new EPS range excludes a $0.17 one-time tariff refund benefit. That is the central development: the Return-to-Growth plan has yet to produce visible improvement, and the guidance cushion is gone.

The quality of the quarter deserves scrutiny. Gross profit and adjusted EBITDA included a $39 million benefit from refining the estimate used to eliminate unrealized profit in inventory. That adds about $30 million to adjusted net income of $59 million, so roughly half of quarterly adjusted earnings came from an item the company says will not recur. It also flattered GAAP gross margin, which rose to 52.9% from 48.8%, and adjusted gross margin, which reached 54.5%. Even with that help, adjusted EBITDA margin contracted 110 basis points to 17.3%, and adjusted EPS still missed. GAAP results swung to a near-breakeven loss of $0.01 per share from a $2.14 loss a year ago. That improvement mostly reflects the absence of last year's $262 million impairment and large tax charge, not a healthier operating business. Cash generation was weak. Operating cash flow dropped to $32 million from $79 million, free cash flow was zero, cash fell to $195 million, and net leverage climbed to 3.4x from 3.0x at the end of 2025.

Beneath the headline, the core trend did not improve. Constant-currency sales fell 7.0%, worse than the 6.3% decline in Q2 and 6.7% in Q1. Excluding items, the decline was 3.8% versus 3.6% in Q2. That undercuts earlier expectations that the plan's benefits would be visible by the fourth quarter. The segment picture worsened broadly:

• Connected Technology Solutions fell 11%, after a 1.5% decline in Q2. Management cited EMEA pricing pressure from low-cost entrants, deferred capital purchases, and a U.S. CAD-CAM inventory shift. Americas CTS sales fell 21.6%.
• Orthodontic and Implant Solutions dropped 17%, from 13.2% in Q2.
• Essential Dental Solutions slipped 4%, from 2.7% in Q2.

Management attributed about three-quarters of the EPS cut to EMEA underperformance and the Middle East conflict. Higher freight costs, a less favorable tax rate, and continued investment account for the rest. Western European dealer destocking is also lasting longer than expected.

The call did preserve some credible green shoots. Wellspect Healthcare posted a record $92 million, up 10%, extending an acceleration from 1.9% constant-currency growth in Q4 2025 through 3.4%, 7.1%, and now double digits. Completion of the U.S. Surity portfolio and new traditional Medicare coverage supported that run. U.S. endodontics returned to growth, up 4%, for the first time since Q2 2025. MIS U.S. sales grew low double digits, value implants rose 7%, and the MIS sales force is set to nearly double by year-end. Other operating signs were also positive:

• Quota-carrying field vacancies fell to mid-single digits from more than 20%.
• North American dealer expansion is largely complete.
• R&D spending is up about 20% year to date.
• Launches such as PrimeScan Connect and Ossix Plus add to the product pipeline.

The problem is scale. These are small, mostly U.S. wins set against a large and deteriorating international and capital-equipment base. The implied fourth-quarter ramp still depends on a capital equipment pickup and favorable mix.

Management's tone shifted noticeably, from describing progress as encouraging to acknowledging that results are not yet where they need to be. The CEO also declined to reaffirm earlier commentary that 2027 would be roughly flat. Bears have legitimate ammunition here. Guidance credibility took a hit, the reduced outlook already embeds the non-recurring inventory benefit, and rising leverage limits flexibility. A proposed settlement of the 2024 Byte securities litigation, covered by insurance, removes one overhang.

Investor sentiment was essentially unchanged and firmly negative, edging to -0.41 from -0.41 at the prior report. Expectations were already low. The market had been punishing the stock well before this release. Shares closed at $10.65 ahead of the report, down 20.3% from the $13.36 opening after the August release and 21.6% below the inter-earnings high. The stock hit a 52-week low of $8.32 on October 15, then rebounded about 28% into the print. Part of that rebound looks like it priced in stabilization this report did not deliver. Earnings Whispers trend signals remain mostly negative, with price, sequential growth, and AVWAP readings all pointing lower.

The bottom line is that Dentsply Sirona's quarter was weaker than the modest headline miss suggests. A one-time accounting benefit propped up margins, the core sales trend failed to improve, cash flow stalled, and management finally cut a guidance range it had defended all year. Wellspect, U.S. endo, and implant execution show the turnaround plan has real pieces. Until EMEA stabilizes and underlying sales stop declining, those green shoots remain too small to change the broader investment setup.